Drug
Mk0457
Mk0457: highest development phase Phase 2, developed by Merck. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| MK0457 NCT00290550 | Phase 2 | Carcinoma, Non-Small-Cell Lung |
Latest
No recent events.
Follow Mk0457 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.